{
    "nctId": "NCT03920488",
    "briefTitle": "Next-Generation Sequencing-based Germline and Somatic Genetic Testing in Triple-negative Breast Cancer",
    "officialTitle": "Evaluating the Feasibility of Next-Generation Sequencing - Based Germline and Somatic Genetic Testing in Triple-negative Breast Cancer. The PERSONA-breast Trial",
    "overallStatus": "RECRUITING",
    "conditions": "Triple Negative Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 264,
    "primaryOutcomeMeasure": "Prevalence of mutations in breast cancer risk-associated genes",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. age between 18 and 60 years\n2. has signed informed consent\n3. histologically confirmed triple negative breast cancer (ER (Estrogen Receptors) \\< 1%, PgR (Progesterone Receptors) \\< 1%, HER2/neu negative (IHC 0, 1+ or 2+ FISH negative).\n4. Stage I-III\n5. Able to undergo surgery (primary or post-neoadjuvant)\n6. Availability of surgical/bioptic material within 6 months from enrolment\n\nExclusion Criteria:\n\n* unable or unwilling to receive genetic counselling",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}